SRRA News and Press, Sierra Oncology Inc. From 11/04/21

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced new retrospective analyses of the momelotinib Phase 3 SIMPLIFY studies will be presented at the 63 rd American Soc...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in three investor conferences in September 2021. Stephen Dilly, MBBS, PhD, President and ...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today updated guidance on the development timeline for its lead product candidate, momelotinib. The company now expects topline data f...

Sierra Oncology (NASDAQ:SRRA): Q2 Non-GAAP EPS of -$1.41; GAAP EPS of -$1.67 misses by $0.06. Cash and cash equivalents of $90.7M Press Release For further details see: Sierra Oncology EPS misses by $0.06

– Enrollment Complete for Pivotal MOMENTUM Phase 3 Trial in Myelofibrosis – – Topline Data Expected in Q1 2022; NDA Filing to Follow in Mid-2022 – Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company with a mission to deliv...

—Combination study to build upon momelotinib’s differentiated potential as a cornerstone myelofibrosis therapy-— Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms...

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to three new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierr...

Today, we take a look at a small developmental company from north of the border. The company's primary drug candidate could be moving towards approval in 2023. A full investment analysis follows in the paragraphs below. For further details see: Sizing Up Sierra Oncology ...

Nano-cap Sierra Oncology (SRRA) announces the completion of enrollment for its pivotal Phase 3 MOMENTUM clinical trial evaluating the novel JAK1, JAK2 and ACVR1 / ALK2 inhibitor momelotinib in myelofibrosis patients who are symptomatic and anemic.The study enrolled 195 patients based on ...

Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial Canada NewsWire —Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif. , June 21, 2021 /CNW/ - Sierra Oncology, Inc. (NASDAQ:...